Bristol Myers Squibb declares $0.63 quarterly dividend

0 min read | Published on 18 Jun 2026, 02:02 AM |Updated on 18 Jun 2026, 02:02 AM

Reviewed by

Suketu GScanX News Team

Key Highlights

Bristol Myers Squibb's Board of Directors declared a quarterly dividend of $0.63 per share on the company's $0.10 par value common stock. The dividend is payable on August 3, 2026, to stockholders of record at the close of business on July 2, 2026.

*this image is generated using AI for illustrative purposes only.

Bristol Myers Squibb announced that its Board of Directors has declared a quarterly dividend of $0.63 per share on the company's $0.10 par value common stock. The dividend is payable on August 3, 2026, to stockholders of record at the close of business on July 2, 2026.

Dividend Details

The following table outlines the key dates and amounts for the dividend distribution:

Detail	Information
Dividend per share	$0.63
Par value of stock	$0.10
Record date	July 2, 2026
Payment date	August 3, 2026

The declaration provides income for shareholders and reflects the Board's decision regarding capital allocation.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How does this dividend declaration align with Bristol Myers Squibb's long-term capital allocation strategy?

What impact might this dividend have on the company's ability to invest in R&D and future growth?

Could this signal a shift in shareholder return policies, such as increased share buybacks?

BMS cuts BREYANZI monitoring proximity to 14 days

0 min read | Published on 17 Jun 2026, 07:33 PM |Updated on 17 Jun 2026, 07:33 PM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

Key Highlights

Bristol Myers Squibb Canada updated the product monograph for BREYANZI, reducing the required proximity to a specialized treatment centre from 28 days to 14 days. Driving restrictions were also lowered from eight weeks to four weeks. Clinical decisions remain with the treating healthcare professional.

*this image is generated using AI for illustrative purposes only.

Bristol Myers Squibb Canada (BMS) has updated the Canadian product monograph for BREYANZI® (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor T (CAR T) cell therapy. The update reduces the duration of certain post-treatment monitoring and activity restrictions for eligible patients following infusion.

The revised guidance lowers the recommended duration for patients to remain in close proximity to a specialized treatment centre from 28 days to 14 days following infusion. Additionally, driving restrictions have been reduced from eight weeks to four weeks.

Clinical decisions regarding patient discharge and ongoing monitoring will continue to be determined by the treating healthcare professional based on individual patient needs.